European Commission Grants Marketing Authorization for Gilead’s Sovaldi (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection

20-01-2014 Business Wire HealthComments (0)

BiotechnologyGilead SciencesSovaldi

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for Sovaldi (sofosbuvir) 400 mg tablets, a once-daily oral nucleotide analogue polymerase inhibitor for the treatment of chronic hepatitis C (CHC) infection in adults, in combination with other antiviral agents (ribavirin (RBV) and pegylated interferon alpha (peg-IFN)). Today’s marketing authorization follows an accelerated assessment by th

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top